Thanks, Chazzle. I'll dedicate this post to you!
In a private msg from Swordman, he said he wasn't following the logic of some of my recent posts and asked if, perhaps, he wasn't understanding what I meant by "objective need." Perhaps there is a problem of communication there.
In Economics, demand, as in Supply and Demand, is defined, in colloquial terms, as "need with money in its hand." If there is no money in the hand of someone who comes to a market, there is no need.
Objective need is not like demand. It is need in the ordinary sense. Money has nothing to do with it.
So if I observe that BP is proposing to supply 9 billion doses of vaccine for Covid, I'm saying they think there is not only a need for that many doses but also, presumably, a demand for those doses because they are not producing those doses for laughs and giggles.
Are they really in that much better shape than CYDY for meeting that kind of demand for their products? I dare say that they have never produced any of their drugs on that scale before on a year basis either. Look how poorly they have performed already!
Now here is an important point to consider - we are sharing this world right now with a virus that has "objective needs." It is driven to replicate and it sees every human as a big pile of food. It is going to pursue its needs like the Borg.
Those who don't want to be taken over by the Borg will have a primary need - to have a properly functioning immune system. So how many people is that? A lot. Leronlimab specializes in bringing an immune system into homeostasis - as far as we know, the best condition it can be in.
So the problem is this - in REALITY, in FACT, BP has never met need or demand on this scale before in its history either. But this is not just a quantitative challenge but also a qualitative challenge. What is BP going to meet this SARS2 challenge with? The target is constantly moving.
At least with Leronlimab, it doesn't matter how the virus mutates if the immune response it triggers can be modulated (Cytokine Storm stopped).
So am I really pumping Cytodyn if I am simply analyzing the size of the problem and the magnitude of the need? No, I don't think so. It is hard to get your head around a solution if you can't visualize the size of the problem. Or the urgency. That is what we are accusing the FDA and the OWS of doing. Why the delay and lack of help?
Sure I want to make some money from Cytodyn stock - but I really, really don't want to become a victim of this virus. Or, for that matter, anything else. But, really, really, not Covid!
In a private msg from Swordman, he said he wasn't following the logic of some of my recent posts and asked if, perhaps, he wasn't understanding what I meant by "objective need." Perhaps there is a problem of communication there.
In Economics, demand, as in Supply and Demand, is defined, in colloquial terms, as "need with money in its hand." If there is no money in the hand of someone who comes to a market, there is no need.
Objective need is not like demand. It is need in the ordinary sense. Money has nothing to do with it.
So if I observe that BP is proposing to supply 9 billion doses of vaccine for Covid, I'm saying they think there is not only a need for that many doses but also, presumably, a demand for those doses because they are not producing those doses for laughs and giggles.
Are they really in that much better shape than CYDY for meeting that kind of demand for their products? I dare say that they have never produced any of their drugs on that scale before on a year basis either. Look how poorly they have performed already!
Now here is an important point to consider - we are sharing this world right now with a virus that has "objective needs." It is driven to replicate and it sees every human as a big pile of food. It is going to pursue its needs like the Borg.
Those who don't want to be taken over by the Borg will have a primary need - to have a properly functioning immune system. So how many people is that? A lot. Leronlimab specializes in bringing an immune system into homeostasis - as far as we know, the best condition it can be in.
So the problem is this - in REALITY, in FACT, BP has never met need or demand on this scale before in its history either. But this is not just a quantitative challenge but also a qualitative challenge. What is BP going to meet this SARS2 challenge with? The target is constantly moving.
At least with Leronlimab, it doesn't matter how the virus mutates if the immune response it triggers can be modulated (Cytokine Storm stopped).
So am I really pumping Cytodyn if I am simply analyzing the size of the problem and the magnitude of the need? No, I don't think so. It is hard to get your head around a solution if you can't visualize the size of the problem. Or the urgency. That is what we are accusing the FDA and the OWS of doing. Why the delay and lack of help?
Sure I want to make some money from Cytodyn stock - but I really, really don't want to become a victim of this virus. Or, for that matter, anything else. But, really, really, not Covid!
10
